{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:15:12Z","timestamp":1788491712240,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40259-021-00501-x","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T16:03:20Z","timestamp":1635264200000},"page":"765-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept"],"prefix":"10.1007","volume":"35","author":[{"given":"Rosanne W.","family":"Meijboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Gardarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"ten Wolde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine C. G.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4087-033X","authenticated-orcid":false,"given":"Thijs J.","family":"Giezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"501_CR1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products; 2014."},{"issue":"10","key":"501_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14712598.2016.1217329","volume":"16","author":"HP Hofmann","year":"2016","unstructured":"Hofmann HP, et al. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel\u00ae). Expert Opin Biol Ther. 2016;16(10):1185\u201395.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"501_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2018-000757","volume":"4","author":"M Matucci-Cerinic","year":"2018","unstructured":"Matucci-Cerinic M, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open. 2018;4(2):1\u20139.","journal-title":"RMD Open"},{"issue":"1","key":"501_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"501_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/annrheumdis-2017-212172","volume":"77","author":"H Matsuno","year":"2018","unstructured":"Matsuno H, Tomomitsu M, Hagino A, Shin S, Lee J, Song YW. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2018;77(4):488\u201394.","journal-title":"Ann Rheum Dis"},{"key":"501_CR6","doi-asserted-by":"crossref","unstructured":"Matucci-Cerinic MJJ et al. Switch between reference etanercept (ETN) and gp2015, an etanercept biosimilar, did not impact efficacy and safety in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase 3 equira study. Arthritis Res Ther. 2019; 609\u2013609.","DOI":"10.1136\/annrheumdis-2018-eular.1368"},{"issue":"2","key":"501_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","volume":"78","author":"B Glintborg","year":"2019","unstructured":"Glintborg B, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192\u2013200.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"501_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/art.40516","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, et al. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheumatol (Hoboken, NJ). 2018;70(9):1408\u201318.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"501_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.semarthrit.2018.07.005","volume":"48(5)","author":"M Scherlinger","year":"2019","unstructured":"Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. 2019;48(5):927\u201332.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"501_CR10","first-page":"42","volume":"4","author":"WD M\u00fcskens","year":"2020","unstructured":"M\u00fcskens WD, Rongen-van Dartel SAA, Teerenstra S, Adang EMM, van Riel PLCM. One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology. Rheumatol Adv Pract. 2020;4(2):42.","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"501_CR11","first-page":"704","volume":"55","author":"ND Vlieland","year":"2016","unstructured":"Vlieland ND, Gardarsdottir H, Bouvy ML, Egberts TCG, van den Bemt BJF. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatol (United Kingdom). 2016;55(4):704\u20139.","journal-title":"Rheumatol (United Kingdom)"},{"key":"501_CR12","unstructured":"European Medicines Agency. Product Information Benepali (etanercept); 2019. p. 167\u2013172."},{"issue":"4","key":"501_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jbspin.2018.12.003","volume":"86","author":"V Sigurdardottir","year":"2019","unstructured":"Sigurdardottir V, Sv\u00e4rd A. Repeated switches between reference product etanercept and biosimilar do not affect disease activity or retention rate of etanercept over 24 months\u2014a cohort study with historical controls. Jt Bone Spine. 2019;86(4):529\u201330.","journal-title":"Jt Bone Spine"},{"issue":"9","key":"501_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/acr.24012","volume":"72","author":"C Gasteiger","year":"2020","unstructured":"Gasteiger C, et al. The effects of message framing on patients\u2019 perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthritis Care Res (Hoboken). 2020;72(9):1323\u201330.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"501_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"501_CR16","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"MG Moghadam","year":"2016","unstructured":"Moghadam MG, et al. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol. 2016;68(8):1810\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"501_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40744-016-0048-9","volume":"3","author":"K Thakur","year":"2016","unstructured":"Thakur K, Biberger A, Handrich A, Rezk MF. Patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a Patient Survey in Europe. Rheumatol Ther. 2016;3(2):245\u201356.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"501_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40259-021-00479-6","volume":"25","author":"AR Kolbe","year":"2021","unstructured":"Kolbe AR, et al., Physician understanding and willingness to prescribe biosimilars: findings from a US National Survey. BioDrugs. 2021;25(3):363\u201372.","journal-title":"BioDrugs."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-021-00501-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T11:49:57Z","timestamp":1637754597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-021-00501-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1007\/s40259-021-00501-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"28 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RWM, HG, MLB, SW, TCGE, and TJG have no potential conflicts of interest related to the content of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of this study was approved by the Institutional Review Board of the Spaarne Gasthuis (reference number 2018.78). Informed consent was waived for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Research data will not be shared.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conception or design of the study. RWM, HG, MLB, and TJG contributed to the acquisition of data and data analysis. All authors participated in the interpretation of the data, contributed to the drafting or revision of the manuscript, and read and gave final approval of the submitted manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}